Skip to main content

Qui Tam Relators: What You Need to Know

Mintz Levin


Date: July 12, 2017

Time: 9:00AM - 10:00AM

Location: Webinar


As the number and novelty of False Claims Act (FCA) cases brought against health care and life sciences companies continue to grow, it is important to understand the role of whistleblowers, who continue to bring the vast majority of FCA cases.

In federal fiscal year 2016:

  • Whistleblowers filed 702 qui tam cases — an average of 13.5 new cases a week. Over 500 of these were against health care and life sciences companies.
  • The federal government recovered $4.7 billion from FCA cases.
  • Whistleblowers received $519 million in relators’ share. Over $450 million of that amount was paid to relators in health care and life sciences cases.

Despite the frequency of such suits and their substantial impact on the health care and life sciences industries, little is known about how relators find their cases, select their counsel, interact with the government, choose their courts, relate to each other, finance their cases and resolve them in the event of a government declination. Understanding the answers to these questions will better position health care and life sciences companies to avoid such suits in the first place and to deal with them should they arise.




Hope S. Foster


Hope regularly defends health care companies in governmental investigations and ensuing cases, conducts internal investigations, and advises providers and manufacturers regarding enforcement issues.
Professional Cropped Lovitch Karen Mintz

Karen S. Lovitch


Karen advises industry clients on regulatory, transactional, operational, and enforcement matters. She has deep experience handling FCA investigations and qui tam litigation for laboratories and diagnostics companies.
Ellyn L. Sternfield is a Mintz Special Counsel with an extensive background in government health care enforcement. She provides insight to clients with compliance concerns and helps clients facing potential state or federal investigations.
As a former official in the Civil Fraud Section of the U.S. Department of Justice, Larry has deep experience handling FCA investigations and qui tam litigation for industry leading health care clients across the country.